Securities code: 300436 securities abbreviation: Fujian Cosunter Pharmaceutical Co.Ltd(300436) Announcement No.: 2022014 Fujian Cosunter Pharmaceutical Co.Ltd(300436)
Announcement on the resolution of the 11th meeting of the 4th board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of directors
The 11th meeting of the 4th board of directors of Fujian Cosunter Pharmaceutical Co.Ltd(300436) (hereinafter referred to as “the company”) was notified by e-mail and telephone on February 12, 2022 and held in the conference room on the second floor of building B, building 10, Fuzhou Software Park, No. 89, Fuzhou software Avenue on February 16, 2022. The meeting was presided over by Mr. Li Guoping, chairman of the board of directors. There were 9 directors who should attend the meeting and 9 directors who actually attended the meeting. The meeting was held in accordance with the provisions of the company law and the articles of association.
2、 Deliberations of the board meeting
(I) deliberated and passed the proposal on changing the subject of commitment of some senior managers to increase their shares in the company
The board of directors agreed to change the subject of the commitment to increase the shares of the company from Dr. Mao Weizhong, the chief scientist of the company, to Mr. Huang Fuhu, the director and deputy general manager of the company, and the amount and duration of the increase remain unchanged.
For details, the company disclosed on cninfo.com on the same day（ http://www.cn.info.com.cn. ）Announcement on changing the commitment subject of some senior managers to increase their shareholding in the company (Announcement No.: 2022016).
The proposal was considered and adopted by 8 votes in favor, 0 against and 0 abstention. Mr. Huang Fuhu, a related director, avoided voting. This proposal must be submitted to the general meeting of shareholders for deliberation.
The independent directors expressed their independent opinions.
(II) through deliberation and adoption of the bill on the conversion of development expenses and the provision for impairment of assets, the Board agreed to terminate Tenofovir disoproxil fumarate tablets’s project (HIV) for the treatment of adult AIDS, and spent part of the R & D development expenditures on some R & D projects and assets impairment provision for some assets, amounting to RMB 9 million 390 thousand and 700 yuan.
For details, the company disclosed on cninfo.com on the same day（ http://www.cn.info.com.cn. ）Announcement on recognition of transfer of development expenditure to expense and provision for asset impairment (Announcement No.: 2022017). The proposal was considered and adopted by 9 votes in favor, 0 against and 0 abstention.
The independent directors expressed their independent opinions.
(III) the proposal on convening the first extraordinary general meeting of shareholders in 2022 was deliberated and adopted
For details, the company disclosed on cninfo.com on the same day（ http://www.cn.info.com.cn. ）Notice on convening the first extraordinary general meeting of shareholders in 2022 (Announcement No.: 2022018).
The proposal was considered and adopted by 9 votes in favor, 0 against and 0 abstention.
3、 Documents for future reference
1. Resolutions of the 11th meeting of the 4th board of directors;
2. Independent opinions of independent directors on matters related to the 11th meeting of the Fourth Board of directors.
It is hereby announced.
Fujian Cosunter Pharmaceutical Co.Ltd(300436) board of directors February 16, 2022
